DiaMedica Pharma (DMAC): היקף יתרות המזומנים של החברה

DMAC (DiaMedica Therapeutics Inc.) - סמל מסחרי של החברה

The prospects for DiaMedica Therapeutics (DMAC) depend on the results of DM199 stroke trials and FDA approval. This cash liquidity chart visualizes the current cash reserves, where 0.04 reflects the latest metric value. Meanwhile, DiaMedica Therapeutics is implementing recombinant proteins to restore organ blood flow, remaining independent of macroeconomic trends and focusing on the protection of brain neurons.

DMAC - מזומנים ושווי מזומנים של החברה DiaMedica Therapeutics Inc בטווח 04.07.2022 - 21.11.2026

פילוחי מדדים ואנליטיקה של חברת DiaMedica Therapeutics Inc. (DMAC)

- שווי מניות ותחזית קונצנזוס למחירים:
ניתוח מקיף של החברה:DiaMedica Therapeutics DMAC
פריט של המותג diamedica.com

The amount of cash reflects the issuer's immediate liquidity and serves as a key indicator of financial viability. This metric aggregates account balances, allowing for the tracking of the burn rate without quarterly distortions. By analyzing cash on hand, an investor assesses the margin of safety for operational activities. For DiaMedica Therapeutics (DMAC), this resource is critically important for funding clinical trials of unique blood flow restoration drugs.